• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pyxis Oncology, Inc. - Common Stock (NQ: PYXS )

    1.700 +0.010 (+0.59%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Pyxis Oncology, Inc. - Common Stock

    Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Participate in Two Upcoming Investor Conferences
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Announces $50 Million Private Placement
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
    Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalities 
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
    From Pyxis Oncology
    Via GlobeNewswire
    New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures Product Safety
    NASDAQ:PYXS Investor Notice: Investigation over Possible Securities Laws Violations by Pyxis Oncology, Inc.
    San Diego, CA -- (SBWIRE) -- 10/05/2023 -- Pyxis Oncology, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
    Via SBWire
    Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Participate in Two Upcoming Investment Conferences
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Successfully Completes Acquisition of Apexigen
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
    From Pyxis Oncology
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.